1122661-16-8

Basic information

• Product Name: 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile
• Synonyms: 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile
• CAS NO: 1122661-16-8
• Molecular Formula: C₁₁H₁₃ClN₂O₂
• Molecular Weight: 240.68612
• Mol File: 1122661-16-8.mol

Chemical Properties

• Melting Point: 118-119℃
• Appearance: /
• Density: 1.24
• CAS DataBase Reference: 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile(1122661-16-8)
• EPA Substance Registry System: 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile(1122661-16-8)

Safety Data

• Hazardous Substances Data: 1122661-16-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile serves as a crucial intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the development of new drugs with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile is employed as a versatile building block for the creation of a wide range of organic compounds. Its functional groups enable various chemical reactions, leading to the formation of diverse molecules with potential applications in different industries.
Safety Precautions:
Due to its potential toxicity and irritant properties, it is essential to handle and store 2-Amino-4-(3-chloropropoxy)-5-methoxyBenzonitrile with care. It should be kept away from sources of ignition and incompatible materials to prevent potential hazards. Additionally, appropriate personal protective equipment should be worn during its use to minimize the risk of exposure.

Upstream product

• 1122661-13-5 4-(3-chloropropoxy)-5-methoxy-2-nitrobenzonitrile 
• 4421-08-3 3-methoxy-4-hydroxybenzonitrile 
• 210918-52-8 4-(3-chloropropoxy)-3-methoxybenzonitrile 

Downstream Products

• 385784-72-5 2-amino-5-methoxy-4-(3-morpholin-4-ylpropoxy)benzonitrile 
• 1048699-01-9 7-(3-chloropropoxy)-6-methoxy-4-(4-trifluoromethylanilino)-1,2,3-benzotriazine 
• 1048699-10-0 7-(3-chloropropoxy)-6-methoxy-4-(4-methylanilino)-1,2,3-benzotriazine 
• 385785-04-6 N’-(2-cyano-5-(3-chloropropoxy)-4-methoxyphenyl)-N,N-dimethylformamidine 

Relevant articles and documents

Quinazoline-1-deoxynojirimycin hybrids as high active dual inhibitors of EGFR and α-glucosidase

A series of novel quinazoline-1-deoxynojirimycin hybrids were designed, synthesized and evaluated for their inhibitory activities against two drug target enzymes, epidermal growth factor receptor (EGFR) tyrosine kinase and α-glucosidase. Some synthesized compounds exhibited significantly inhibitory activities against the tested enzymes. Comparing with reference compounds gefitinib and lapatinib, compounds 7d, 8d, 9b and 9d showed higher inhibitory activities against EGFR (IC50: 1.79–10.71 nM). Meanwhile the inhibitory activities of 7d, 8d and 9c against α-glucosidase (IC50 = 0.14, 0.09 and 0.25 μM, respectively) were obvious higher than that of miglitol (IC50 = 2.43 μM), a clinical using α-glucosidase inhibitor. Interestingly, compound 9d as a dual inhibitor showed high inhibitory activity to EGFRwt tyrosine kinase (IC50 = 1.79 nM), also to α-glucosidase (IC50 = 0.39 μM). The work could be very useful starting point for developing a new series of enzyme inhibitors targeting EGFR and/or α-glucosidase.

Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells

A series of novel 4-anilinoquinazoline derivatives with (E)-propen-1-yl moiety were designed, synthesized and evaluated for biological activities in vitro. Most compounds exhibited highly antiproliferative activities against all tested tumor cell lines in

Synthesis and biological evaluation of substituted 1,2,3-benzotriazines and pyrido[3,2-d]-1,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2

A novel series of substituted 1,2,3-benzotriazines and pyrido[3,2-d]-1,2,3- triazines were synthesized. The abilities of these compounds to inhibit the VEGFR-2 kinase activity and the proliferation of human microvascular endothelial cells (MVECs) were det

AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF

The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as a

THE AROMATIC RING TRIAZINE DERIVATIVES AND THE USES THEREOF

The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I. including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as a

Design, synthesis, and antitumor activities of some novel substituted 1,2,3-benzotriazines

A series of novel substituted 1,2,3-benzotriazines based on the structures of vatalanib succinate (PTK787) and vandetanib (ZD6474) were designed and synthesized. The antiproliferative effects of these compounds were tested on microvascular endothelial cel